Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/26/24
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/12/24
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 08/05/24
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their ArteriesGlobeNewsWire • 07/16/24
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest FacilityGlobeNewsWire • 06/28/24
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?Zacks Investment Research • 06/06/24
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for HypercholesterolemiaGlobeNewsWire • 05/20/24
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The StockSeeking Alpha • 05/20/24
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®GlobeNewsWire • 05/14/24
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat EstimatesZacks Investment Research • 05/07/24
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityGlobeNewsWire • 04/07/24